Navigation Links
BullMarket.com Updates Outlook on Biotech Stocks
Date:3/12/2009

PRINCETON, N.J., March 12 /PRNewswire-FirstCall/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with updated coverage of several biotech stocks, including Amgen (Nasdaq: AMGN), Gilead Sciences (Nasdaq: GILD), Celgene (Nasdaq: CELG), Genzyme (Nasdaq: GENZ), and Vertex Pharmaceuticals (Nasdaq: VRTX).

All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which outperformed the S&P 500 by 15% in 2008.

Start your 14-day free trial today:

https://www.bullmarket.com/subscribe/pr/?refer=BMR500P

In its daily report, BullMarket.com wrote: "The Pfizer-Wyeth combo, followed quickly by the Merck-Schering announcement, laid waste to the notion that Big Pharma was coveting successful biotechs. (It is, we suppose, another example of why investors should cover their ears when they hear 'conventional wisdom' and 'Wall Street' in the same sentence.) Granted, Europe's Roche Holdings today bought the portion of Genentech that it doesn't already own, but in this case, the two companies have a long-standing relationship and the latter made sure it extracted the highest possible price."

BullMarket.com looked at the following topics, among others:

-- What drug candidate could turn Amgen back into a growth story in 2010?

-- Why does Vertex's recent purchase of ViroChemPharma look like a smart move?

-- How does Celgene's principal drug Revlimid have an advantage over other multiple myeloma treatments?

-- What event has been a real black eye for Genzyme?

-- What recent event demonstrates that it will be difficult for generic drug companies to produce generic versions of biologics?

-- Is now the time to buy biotech stocks, and which ones look the most promising?

About BullMarket.com:

Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:

Marcie Martin, Bull Market Report, +1-888-278-5515


'/>"/>
SOURCE Indie Research Advisors, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BullMarket.com Examines Stem Cell Stocks
2. BullMarket.com Examines Healthcare IT Stocks
3. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
4. Cell Therapeutics Updates Shareholders on Trading
5. Service Corporation International Updates Fourth Quarter 2008 Guidance
6. NCCN Updates Breast Cancer and Breast Cancer Risk Reduction Guidelines
7. LegalView Updates Avandia Information Portal With New Articles Detailing Potentially Dangerous Side Effects
8. Medical Management Corporation Updates Medical Billing Services
9. Omnicell Updates 2008 Year End Guidance and Announces Company Reorganization
10. LegalView Updates Peanut Butter Recall Information Portal with Info on Salmonella Contaminations Among Several Tainted Food Products
11. CEO of Traxxec, Inc. updates on Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... the premiere organization in North America for the scientific development, healthcare training and ... Annual Scientific Session, and its 2017 AAT Member Certification Qualification Courses for Technicians, ...
(Date:1/23/2017)... ... , ... "ProRandom is a set of camera tools that allow video editors to integrate up ... X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video ... footage. ProRandom works by using a virtual camera to create the illusion of a ...
(Date:1/23/2017)... ... 2017 , ... “Crossing the Bar”: a moving and eloquent drama depicting ... the Bar” is the creation of published author, Charlotte Hotte, a North Carolina native, ... the inspiration of the book to her sister, Denise, wishes to acknowledge her savior, ...
(Date:1/22/2017)... ... January 22, 2017 , ... Phytocéane invites clients to ... the rest of the world with ZANZIBAR MILKY CREAM. Inspired by the beauty of ... like Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, velvety body ...
(Date:1/21/2017)... ... 21, 2017 , ... Salveo for life, a company that distributes an effervescent ... United States as part of its presence to expand its market reach. , Using ... the productions of nasty toxins as a result of drinking alcohol, eliminating those toxins ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute Medical,s ... high risk for acute kidney injury (AKI) after ... globally-recognized care guidelines significantly improved outcomes ... AKI more than 33 percent, according to a ... journal Intensive Care Medicine. ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are factors ... BCC Research reveals in its new report that markets in developing ... strong growth due to rising government healthcare spending, increased levels of healthcare ... Reading ... BCC ...
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
Breaking Medicine Technology: